Vascular BioSciences
Vascular Biosciences (VBS) is an innovative biomedical company developing breakthrough solutions to critical military and civilian medical challenges including: Military Infectious Diseases, Sepsis, Combat Casualty Care, Acute High Altitude Pulmonary Edema, and CBRN medical countermeasures. Our inflammation homing peptide, CARSKNKDC (CAR), enables increased localized concentrations of drugs to dramatically improve therapeutic outcomes with reduced side-effects. CAR converts systemically administered drugs into precision medicines. CAR peptide, by itself, also dramatically speeds up wound healing.
Industries
Nr. of Employees
small (1-50)
Vascular BioSciences
72 Santa Felicia Dr Goleta, CA 93117
Patents
Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same
2023-05-09 • US-11642391-B2
View DetailsOrally active, cell-penetrating homing peptide and methods using same
2022-12-13 • US-11524077-B2
View DetailsCar peptide for homing, diagnosis and targeted therapy for pulmonary and fibrotic disorders
2018-08-07 • US-10039838-B2
View DetailsOrally active, cell-penetrating homing peptide and methods of using same
2017-05-23 • US-9655973-B2
View DetailsMethods for increasing the selective efficacy of gene therapy using CAR peptide and heparan-sulfate mediated macropinocytosis
2017-03-28 • US-9603890-B2
View DetailsMethods of novel therapeutic candidate identification through gene expression analysis in vascular related diseases
2016-11-22 • US-9499816-B2
View Details
Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same
2023-05-09 • US-11642391-B2
View DetailsOrally active, cell-penetrating homing peptide and methods using same
2022-12-13 • US-11524077-B2
View DetailsCar peptide for homing, diagnosis and targeted therapy for pulmonary and fibrotic disorders
2018-08-07 • US-10039838-B2
View DetailsOrally active, cell-penetrating homing peptide and methods of using same
2017-05-23 • US-9655973-B2
View DetailsMethods for increasing the selective efficacy of gene therapy using CAR peptide and heparan-sulfate mediated macropinocytosis
2017-03-28 • US-9603890-B2
View DetailsMethods of novel therapeutic candidate identification through gene expression analysis in vascular related diseases
2016-11-22 • US-9499816-B2
View DetailsProducts
CARSKNKDC (CAR) Peptide
Inflammation-homing peptide platform designed to increase localized delivery of therapeutics to inflamed, infected, and injured tissues, improving therapeutic efficacy while reducing systemic side effects. The CAR peptide has demonstrated preclinical efficacy in wound healing, sepsis, infectious disease, and pulmonary injury models, with potential applications in targeted therapeutics and acute inflammatory conditions.
Endoarterial Biopsy Catheter
Minimally invasive endovascular biopsy platform designed to obtain arterial tissue samples for vascular pathology and molecular analysis, enabling direct access to diseased vascular tissue.
Molecular Diagnostics Technology
Advanced molecular diagnostics platform utilizing vascular tissue analysis, genomic profiling, and bioinformatics to identify disease-specific biomarkers and support earlier diagnosis, therapeutic monitoring, and personalized treatment strategies for vascular and inflammatory diseases.
CARSKNKDC (CAR) Peptide
Inflammation-homing peptide platform designed to increase localized delivery of therapeutics to inflamed, infected, and injured tissues, improving therapeutic efficacy while reducing systemic side effects. The CAR peptide has demonstrated preclinical efficacy in wound healing, sepsis, infectious disease, and pulmonary injury models, with potential applications in targeted therapeutics and acute inflammatory conditions.
Endoarterial Biopsy Catheter
Minimally invasive endovascular biopsy platform designed to obtain arterial tissue samples for vascular pathology and molecular analysis, enabling direct access to diseased vascular tissue.
Molecular Diagnostics Technology
Advanced molecular diagnostics platform utilizing vascular tissue analysis, genomic profiling, and bioinformatics to identify disease-specific biomarkers and support earlier diagnosis, therapeutic monitoring, and personalized treatment strategies for vascular and inflammatory diseases.
Expertise Areas
- Targeted therapeutics for pulmonary and cardiovascular diseases
- Minimally invasive vascular tissue sampling
- Molecular diagnostics for personalized medicine
- Drug delivery platform engineering
Key Technologies
- Peptide-mediated targeted drug delivery
- Liposome-based therapeutic delivery
- Percutaneous endoarterial biopsy technology
- Next-generation sequencing
Key People
Chief Executive Officer, Chairman
Chief Executive Officer, Chairman
News & Updates
Received grant in collaboration with VA Hospital of Northern California for peptide-targeted liposomal therapy research.
Received federal grant funding to develop peptide-based targeted therapy for pulmonary hypertension.
Grant to develop a cyclic peptide targeting approach for pulmonary hypertension.
Received HUD designation from the FDA for minimally invasive endoarterial biopsy catheter in pulmonary arterial hypertension.
Named a winner in a national biotech innovation competition recognizing drug development pipelines.
Received $1.2 million contract to develop peptide-based therapeutic adjuvant for pulmonary arterial hypertension targeted therapy.
Received grant in collaboration with VA Hospital of Northern California for peptide-targeted liposomal therapy research.
Received federal grant funding to develop peptide-based targeted therapy for pulmonary hypertension.
Grant to develop a cyclic peptide targeting approach for pulmonary hypertension.
Received HUD designation from the FDA for minimally invasive endoarterial biopsy catheter in pulmonary arterial hypertension.
Named a winner in a national biotech innovation competition recognizing drug development pipelines.
Received $1.2 million contract to develop peptide-based therapeutic adjuvant for pulmonary arterial hypertension targeted therapy.